

# Carin A Uyl-De Groot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/386814/publications.pdf>

Version: 2024-02-01

93  
papers

1,326  
citations

361413

20  
h-index

477307

29  
g-index

96  
all docs

96  
docs citations

96  
times ranked

2236  
citing authors

#	ARTICLE	IF	CITATIONS
1	Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS ONE, 2017, 12, e0182613.	2.5	91
2	Sustainability and affordability of cancer drugs: a novel pricing model. Nature Reviews Clinical Oncology, 2018, 15, 405-406.	27.6	55
3	&lt;p&gt;First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 1413-1421.	2.0	51
4	A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European Journal of Cancer, 2019, 123, 58-71.	2.8	45
5	Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry. European Urology Focus, 2018, 4, 694-701.	3.1	43
6	Long-term Outcomes in Patients With Multiple Myeloma. HemaSphere, 2018, 2, e45.	2.7	38
7	Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry. Urology, 2016, 95, 121-127.	1.0	34
8	A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. European Journal of Haematology, 2016, 96, 198-208.	2.2	33
9	Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe. Cancers, 2020, 12, 2313.	3.7	33
10	Two decades of targeted therapies in acute myeloid leukemia. Leukemia, 2021, 35, 651-660.	7.2	33
11	THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS. International Journal of Technology Assessment in Health Care, 2016, 32, 46-53.	0.5	32
12	Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. European Journal of Health Economics, 2020, 21, 153-164.	2.8	30
13	Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view. European Journal of Haematology, 2020, 105, 203-215.	2.2	29
14	Impact of <sc>DNA</sc> damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. International Journal of Cancer, 2021, 148, 385-395.	5.1	28
15	Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences. Value in Health, 2017, 20, 627-636.	0.3	27
16	Expanded Access as a source of real-world data: An overview of FDA and EMA approvals. British Journal of Clinical Pharmacology, 2020, 86, 1819-1826.	2.4	27
17	Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy. Pharmacoeconomics, 2018, 36, 91-103.	3.3	26
18	What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the Challenges. Value in Health, 2019, 22, 1318-1328.	0.3	26

#	ARTICLE	IF	CITATIONS
19	Dispelling the myths around cancer care delivery: It's not all about costs. <i>Journal of Cancer Policy</i> , 2014, 2, 22-29.	1.4	25
20	Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. <i>Future Oncology</i> , 2020, 16, 1371-1384.	2.4	25
21	Potential cost savings owing to the route of administration of oncology drugs. <i>Anti-Cancer Drugs</i> , 2018, 29, 791-801.	1.4	23
22	Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future. <i>HemaSphere</i> , 2021, 5, e524.	2.7	23
23	Health-related quality of life of multiple sclerosis patients: a European multi-country study. <i>Archives of Public Health</i> , 2021, 79, 39.	2.4	21
24	Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective. <i>Value in Health</i> , 2021, 24, 1686-1699.	0.3	21
25	Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. <i>Value in Health</i> , 2016, 19, 834-843.	0.3	18
26	Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 825-831.	1.0	17
27	Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. <i>Haematologica</i> , 2019, 104, 1026-1035.	3.5	17
28	Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 71, 3136-3143.	5.8	17
29	A Systematic Review of Cost-Effectiveness Studies of Interventions With a Personalized Nutrition Component in Adults. <i>Value in Health</i> , 2021, 24, 325-335.	0.3	17
30	A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26651.	1.5	16
31	Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study. <i>European Journal of Cancer</i> , 2021, 154, 111-119.	2.8	16
32	Systematic reviews as a "lens of evidence": Determinants of cost-effectiveness of breast cancer screening. <i>Cancer Medicine</i> , 2019, 8, 7846-7858.	2.8	15
33	Economic evaluations of big data analytics for clinical decision-making: a scoping review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 1466-1475.	4.4	15
34	Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study. <i>Lung Cancer</i> , 2020, 141, 89-96.	2.0	15
35	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , 2020, 12, 1003.	3.7	15
36	Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia. <i>Journal of Medical Economics</i> , 2009, 12, 164-169.	2.1	14

#	ARTICLE	IF	CITATIONS
37	A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27458.	1.5	14
38	Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. <i>Haematologica</i> , 2004, 89, 1109-17.	3.5	14
39	Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer. <i>Value in Health</i> , 2015, 18, 84-90.	0.3	12
40	Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. <i>Leukemia Research</i> , 2016, 50, 37-45.	0.8	12
41	Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib?. <i>Value in Health</i> , 2014, 17, 245-253.	0.3	11
42	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 579-588.	1.4	11
43	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 572-578.	1.4	11
44	Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non-Small Cell Lung Cancer Using Real-World Data. <i>Value in Health</i> , 2019, 22, 322-331.	0.3	11
45	Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab. <i>Breast</i> , 2020, 52, 71-77.	2.2	11
46	Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare. <i>Value in Health</i> , 2021, 24, 1038-1044.	0.3	11
47	Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals. <i>BMJ Open</i> , 2022, 12, e052186.	1.9	11
48	Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	11
49	Costs of Peripheral Blood Progenitor Cell Transplantation Using Whole Blood Mobilised by Filgrastim as Compared With Autologous Bone Marrow Transplantation in Non-Hodgkin's Lymphoma. <i>Pharmacoeconomics</i> , 1999, 15, 305-311.	3.3	10
50	Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands. <i>Health Economics Review</i> , 2018, 8, 13.	2.0	10
51	Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach. <i>Cancers</i> , 2021, 13, 2308.	3.7	10
52	Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 1429-1442.	3.3	10
53	Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmacoeconomic assessment. <i>European Journal of Haematology</i> , 2020, 105, 635-645.	2.2	8
54	Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. <i>JAMA Network Open</i> , 2021, 4, e213497.	5.9	7

#	ARTICLE	IF	CITATIONS
55	Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement. <i>Health Policy</i> , 2015, 119, 186-194.	3.0	6
56	Practice Variation in Skin Cancer Treatment and Follow-Up Care: A Dutch Claims Database Analysis. <i>Dermatology</i> , 2021, 237, 1000-1006.	2.1	6
57	Fair Pricing of Innovative Medicines: An EHA Position Paper. <i>HemaSphere</i> , 2020, 4, e488.	2.7	6
58	The economics of improved cancer survival rates: better outcomes, higher costs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 283-292.	1.4	5
59	Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e946-e956.	1.9	5
60	Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28588.	1.5	5
61	A clinician's guide for developing a prediction model: a case study using real-world data of patients with castration-resistant prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2067-2075.	2.5	5
62	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1851-1859.	2.8	4
63	Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model. <i>European Journal of Haematology</i> , 2018, 101, 676-683.	2.2	4
64	Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e233-e253.	1.9	4
65	Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 240.	2.4	4
66	Response to Open Peer Commentary "Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs". <i>American Journal of Bioethics</i> , 2020, 20, W4-W5.	0.9	4
67	Early technology assessment of using whole genome sequencing in personalized oncology. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 343-351.	1.4	4
68	The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon- $\beta$ 1a Therapy Versus Injectable Interferon- $\beta$ 1a Treatment in Relapsing/Remitting Multiple Sclerosis. <i>Pharmacoeconomics</i> , 2022, 40, 91-108.	3.3	4
69	Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands. <i>Blood</i> , 2018, 132, 3555-3555.	1.4	4
70	Primary care in cancer control: towards mature cancer care. <i>Lancet Oncology</i> , The, 2015, 16, 1226-1227.	10.7	3
71	Cost-effectiveness in colorectal cancer: challenges on quality and comparability. <i>Colorectal Cancer</i> , 2016, 5, 21-31.	0.8	3
72	Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe. <i>Pharmacogenomics</i> , 2018, 19, 213-226.	1.3	3

#	ARTICLE	IF	CITATIONS
73	Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran. PLoS ONE, 2018, 13, e0205079.	2.5	3
74	Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial. Clinical Drug Investigation, 2022, 42, 163-175.	2.2	3
75	Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer. Translational Oncology, 2022, 20, 101418.	3.7	3
76	The DRUG Access Protocol: access inequality and European harmonisation. Lancet Oncology, The, 2022, 23, e202.	10.7	3
77	Using Appropriate Methods in Cost-Effectiveness Analyses: The Case of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 2109-2110.	2.0	2
78	CHANGING NURSING CARE TIME AS AN EFFECT OF CHANGED CHARACTERISTICS OF THE DIALYSIS POPULATION. Journal of Renal Care, 2020, 46, 161-168.	1.2	2
79	How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care. BMC Medical Informatics and Decision Making, 2021, 21, 336.	3.0	2
80	Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives. BMJ Open, 2022, 12, e055165.	1.9	2
81	Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review. Cancers, 2022, 14, 2444.	3.7	2
82	Reply to "Economic comments on proposal for a novel cancer drug pricing model". Nature Reviews Clinical Oncology, 2018, 15, 588-588.	27.6	1
83	Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review. Value in Health, 2020, 23, 1497-1508.	0.3	1
84	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Focus, 2021, 7, 788-796.	3.1	1
85	Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands. Melanoma Research, 2021, 31, 249-257.	1.2	1
86	Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view. Expert Review of Anticancer Therapy, 2021, 21, 1-12.	2.4	1
87	Adjuvant treatment in patients with melanoma: The planning of scanning. European Journal of Cancer, 2021, 157, 306-307.	2.8	1
88	Response to "Comment on "Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy". Pharmacoeconomics, 2018, 36, 381-382.	3.3	0
89	Reply to "Response to proposal for a novel cancer drug pricing model". Nature Reviews Clinical Oncology, 2018, 15, 528-529.	27.6	0
90	The Cost of Healthcare for Pediatric Patients with Sickle Cell Disease. Blood, 2019, 134, 1030-1030.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. <i>Drugs - Real World Outcomes</i> , 2022, , 1.	1.6	0
92	Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare. <i>Value in Health</i> , 2022, , .	0.3	0
93	Comment on: "Premedication prior to PEG-asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia". <i>Pediatric Blood and Cancer</i> , 2022, 69, e29474.	1.5	0